These observations suggest a potential opportunity for the PARP1-selective inhibitor niraparib to serve as an effective treatment for NSCLC patients with ATM mutations who cannot benefit from EGFR-targeted therapies. Here, ATM is linked to non-small cell lung carcinoma.